Curis Lifesciences Ltd Share Price

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act 1932 in the name and style of M/s Loreto Pharmaceutacals pursuant to a Deed of Partnership dated 2 June 2010. Thereafter M/s Loreto Pharmaceutacals was converted from Partnership Firm to a Private Limited Company as Curis Lifesciences Private Limited and received a Certificate of Incorporation dated on March 23rd 2016 issued by Registrar of Companies Ahmedabad. Subsequently Company was converted into a Public Limited Company and the name of the Company was changed from Curis Lifesciences Private Limited to Curis Lifesciences Limited vide certified incorporated upon the conversion dated August 9 2024 issued by the Central Processing Centre Manesar.Companys business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic. The business is majorly on product to product basis with different marketers. Company has commenced manufacturing facility in year 2017 hence it has experience of more than 7 years in the current line of business of the Company. The manufacturing facility of the Company is installed with capacity to manufacture 138 Crore tables / year 15.75 Crore Capsules / year 1080 Kilolitre Oral Liquid/ year 270 Tons external preparation / year and 45 Tons sterile ophthalmic ointment / year. It deal in Pharmaceutical products like Tablets Capsules External Preparations Oral Liquid Sterile Ophthalmic Ointments etc.The Companys past and present clientele includes renowned pharma marketers and manufactures namely Arova Pharma Express Pharmaceuticals Private Limited Angle Biogenics Private Limited Centurion Healthcare Private Limited Costcon Healthcare LLP J.B. Chemical Pharmaceuticals Limited Venus international Makers Laboratories Limited and Torikaa Pharmaceuticals Limited etc. pharmaceutical manufacturing facility are situated at Sanand GIDCII in Ahmedabad district of Gujarat which offers easy and convenient accessibility.Company is planning an Initial Public Issue of upto 2250000 Equity Shares of face value of Rs 10 each through fresh issue..

Revenue: ₹9.12Cr as on June 2024 (Q1 FY25)
Net Profit: ₹1.20Cr as on June 2024 (Q1 FY25)
Listing date: 14 Nov, 2025
Chairperson Name: Dharmesh Dasharathbhai Patel